Indicated for: cancer
Route of administration: injectable
Substance: dactynomicin (antineoplastic agent)
ATC: L01DA01 (Antineoplastic and immunomodulating agents | Cytotoxic antibiotics and related substances | Actinomycines)
Dactinomycin is a chemotherapy medication used for the treatment of certain types of cancer, such as Wilms tumors, rhabdomyosarcoma, and choriocarcinoma. It works by inhibiting RNA synthesis, leading to the cessation of cell division and the destruction of cancer cells.
The medication is administered via intravenous infusion, with the dose determined by the physician based on the type of cancer and the patient's weight. Common side effects include nausea, vomiting, bone marrow suppression, and stomatitis.
Dactinomycin is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. It should also be used with caution in patients with hepatic or renal impairment.
This medication is an important option in cancer treatment, helping to reduce tumor size and improve the prognosis of affected patients.